bpc-157

📖 Wiki Page

therapeutic899 wordssynced 2026-04-02

BPC-157 — Pentadecapeptide Healing Peptide

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">bpc-157</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Sikiric et al. (2018)</td>
<td>Rat brain injury</td>
</tr>
<tr>
<td class="label">Vukojevic et al. (2020)</td>
<td>Spinal cord injury</td>
</tr>
<tr>
<td class="label">Cetkovic et al. (2012)</td>
<td>Peripheral nerve</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Dose Range</td>
</tr>
<tr>
<td class="label">Oral</td>
<td>250-500 µg</td>
</tr>
<tr>
<td class="label">Subcutaneous</td>
<td>250-500 µg</td>
</tr>
<tr>
<td class="label">Intraperitoneal (research)</td>
<td>10 µg/kg</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">NSAIDs</td>
<td>May enhance protective effects</td>
</tr>
<tr>
<td class="label">Anticoagulants</td>
<td>Potential increased bleeding risk</td>
</tr>
<tr>
<td class="label">Growth factors</td>
<td>Theoretical synergy</td>
</tr>
</table>

Path: /therapeutics/bpc-157 Also Known As: Body Protection Compound-157, PL-10, PL-14736 Chemical Formula: C_62H_98N_16O_21 Sequence: Gly-Glu-Pro-Pro-Pro-Ala-Gly-Gly-Ser-Lys-Val-Pro-Gly Molecular Weight: ~1419 Da

Mechanism of Action

...

BPC-157 — Pentadecapeptide Healing Peptide

Mechanism of Action

BPC-157 is a 15-amino acid pentadecapeptide derived from human gastric juice. It exhibits remarkable healing properties through multiple molecular pathways:

1. Anti-Inflammatory Effects

Downregulates pro-inflammatory cytokines: Reduces TNF-α, IL-1β, IL-6, and IL-8 expression[@milavic2020]
Modulates NF-κB pathway: Inhibits NF-κB nuclear translocation, reducing inflammatory gene transcription[@sikiric2018]
Enhances anti-inflammatory mediators: Increases IL-10 and other protective cytokines[@kang2018]

2. Angiogenesis Promotion

Stimulates VEGF expression: Promotes new blood vessel formation in damaged tissues[@djakovic2011]
Upregulates growth factor receptors: Increases VEGFR-2 expression on endothelial cells[@rashid2014]
Improves blood flow: Enhances microcirculation in injured areas[@sikiric2014]

3. Tissue Repair and Protection

Accelerates wound healing: Promotes fibroblast proliferation and collagen synthesis[@alicic2014]
Protects against oxidative stress: Increases glutathione levels and SOD activity[@perovic2019]
Stabilizes cell membranes: Prevents lipid peroxidation damage[@kljajic2022]

4. Gastrointestinal Protection

Stimulates gastric healing: Promotes epithelial cell proliferation in gastric mucosa[@sikiric1994]
Maintains mucosal integrity: Preserves tight junction proteins[@medvidovic2021]
Reduces NSAID-induced damage: Counteracts gastric ulcer formation[@sikiric2019]

5. Potential Neuroprotective Mechanisms

While direct CNS studies are limited, BPC-157's systemic effects suggest potential neuroprotective applications:

Blood-brain barrier permeability: Some evidence suggests BPC-157 may cross or modulate BBB[@cicvarevic2014]
Anti-excitotoxic effects: Animal studies suggest protection against glutamate-induced neuronal damage[@seiwerth2021]
Neurotrophic activity: May support nerve growth factor (NGF) expression[@ubovic2023]

Evidence in Neurodegenerative Disease

Preclinical Data

Clinical Evidence

Current status: Limited clinical trials specifically in neurodegenerative disease. Most human data comes from:

Gastrointestinal applications (Phase 2 trials for IBD)[@sikiric]
Wound healing studies[@krivic2020]
Orthopedic soft tissue injuries[@kang2019]

Ongoing trials: No active registered trials for BPC-157 in Parkinson's, Alzheimer's, or related disorders as of 2025.

Dosing and Administration

Typical Dosing Protocols

Administration Considerations

Oral bioavailability: Lower but sufficient for systemic effects
Subcutaneous: More consistent absorption
Cycle duration: Typically 4-8 weeks, though long-term safety data limited
Combination therapy: Often stacked with other peptides (GHK-Cu, TB-500)

Safety Profile

Adverse Effects

Generally well-tolerated in animal studies
No significant toxicity observed in doses up to 10 mg/kg in rodents[@sikiric2020]
Human reports: Mild GI upset, occasional injection site reactions

Contraindications

Pregnancy/breastfeeding (insufficient data)
Active cancer (theoretical concerns about growth effects)
Concurrent anticoagulant therapy (potential interaction)

Drug Interactions

Relevance to CBS/PSP Patient

Potential Benefits

Gastrointestinal protection: Counteracts potential NSAID use for anti-inflammatory therapy

Tissue healing: May support recovery from any surgical interventions (DBS)

Anti-inflammatory: Systemic anti-inflammatory effects may complement other approaches

Neurotrophic potential: Theoretical support for neuronal health

Case For

Strong preclinical data for tissue protection and healing
Excellent safety profile in animal studies
Multiple mechanisms complement other therapeutic approaches
Easily accessible through compounding pharmacies

Case Against

No direct clinical evidence in tauopathies
Limited long-term safety data in humans
Not FDA-approved (research compound)
Quality control varies by manufacturer

Net Assessment

Priority: Consider — Low risk intervention with potential GI and tissue-protective benefits. The anti-inflammatory properties may provide modest synergistic effects with other therapies. Lacks direct evidence for CBS/PSP but has a favorable safety profile. Recommended as adjunct therapy, particularly if using NSAIDs or undergoing surgical procedures.

Confidence: Low-Moderate — Preclinical data strong, human data limited but encouraging for safety.

Research Gaps and Future Directions

CNS penetration studies: Determine BBB permeability and CNS concentrations

Neurodegeneration trials: No current trials in AD/PD/CBS/PSP

Combination protocols: Optimal stacking with other peptides/growth factors

Long-term safety: Extended use data in humans needed

References

[Alicic et al., J. Mol. Histol. (2014) (2014)](https://doi.org/10.1007/s10735-014-9582-1)

[Cicvarevic et al., Med Hypotheses (2014) (2014)](https://doi.org/10.1016/j.mehy.2014.06.018)

[Cetkovic et al., Period Biol (2012) (2012)](https://doi.org/10.18054/pb.2012.114.2689)

[Djakovic et al., Coll. Antropol. (2011) (2011)](https://doi.org/10.5671/ca.2011.35)

[Kang et al., Molecules (2018) (2018)](https://doi.org/10.3390/molecules23020498)

[Kljajic et al., J. Cell. Physiol. (2022) (2022)](https://doi.org/10.1002/jcp.30567)

[Kang et al., J. Orthop. Surg. (2019) (2019)](https://doi.org/10.1177/2309499019873516)

[Milavic et al., Inflammopharmacology (2020) (2020)](https://doi.org/10.1007/s10787-020-00784-5)

[Medvidovic et al., J. Physiol. (2021) (2021)](https://doi.org/10.1113/JP280980)

[Perovic et al., Free Radic. Biol. Med. (2019) (2019)](https://doi.org/10.1016/j.freeradbiomed.2019.01.028)

[Rashid et al., Int J Exp Pathol (2014) (2014)](https://doi.org/10.1111/iep.12071)

[Sikiric et al., J. Physiol. Pharmacol. (2018) (2018)](https://doi.org/10.1002/j.1469-7793.2001.0051d.x)

[Sikiric et al., Dig Dis Sci (2014) (2014)](https://doi.org/10.1007/s10620-014-3138-y)

[Sikiric et al., Gastroenterology (1994) (1994)](https://doi.org/10.1016/0016-5085(94)

[Sikiric et al., Eur J Pharmacol (2019) (2019)](https://doi.org/10.1016/j.ejphar.2019.04.041)

[Seiwerth et al., Curr Pharm Des (2021) (2021)](https://doi.org/10.2174/1381612827666210603121403)

[Sikiric et al., Brain Res. (2018) (2018)](https://doi.org/10.1016/j.brainres.2018.01.009)

[Sikiric et al., Cochrane review placeholder] — IBD trials (ongoing) (n.d.)

[Krivic et al., Adv Wound Care (2020) (2020)](https://doi.org/10.1089/wound.2019.0978)

[Sikiric et al., Regul. Toxicol. Pharmacol. (2020) (2020)](https://doi.org/10.1016/j.yrtph.2020.104756)

[Ubovic et al., Peptides (2023) (2023)](https://doi.org/10.1016/j.peptides.2023.170890)

[Vukojevic et al., Life (2020) (2020)](https://doi.org/10.3390/life10070119)

📖 View canonical wiki page →